A new PCR-based mass spectrometry system for high-risk HPV, part II: Clinical trial

American Journal of Clinical Pathology

Volumn 136, Issue 6, 2011, Pages 920-923

  Du, Hui ^a   Yi, Ji ^b   Wu, Ruifang ^a   Belinson, Suzanne E ^c   Qu, Xinfeng ^c   Yang, Bin ^d   Wang, Chun ^a   Yi, Xin ^b   Belinson, Jerome L ^a,d  

^a PEKING UNIVERSITY SHENZHEN HOSPITAL   (China)

^b BGI SHENZHEN   (China)

^c Preventive Oncology International   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cervical cancer; HPV; Human papillomavirus; MALDI TOF; Matrix assisted laser desorption ionization time of flight mass spectrometry system; Screening

Indexed keywords

ADULT; ARTICLE; CHINA; CLINICAL TRIAL; COLPOSCOPY; CYTOLOGY; FEMALE; HUMAN; HUMAN CELL; INFECTION RISK; MASS SCREENING; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UTERINE CERVIX; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE ENDOCERVIX; WART VIRUS;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; CHINA; DNA, VIRAL; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 82655181344     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPJDAORUY4EYR6     Document Type: Article

References (15)

1. Suba EJ, Raab SS. Lessons learned from successful Papanicolaou cytology cervical cancer prevention in the socialist republic of Vietnam [published online ahead of print March 10, 2011]. Diagn Cytopathol. doi:10.1002/dc.21655.
2. Sankaranarayanan R, Esmy PO, Rajkumar R, et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet. 2007;370:398-406. (Pubitemid 47176655)
3. Cuzick J, Clavel C, Petry KU, et al. European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095-1101. (Pubitemid 44116919)
4. Qiao Y-l, Sellors JW, Eder PS, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a crosssectional study of clinical accuracy in rural China. Lancet Oncol. 2008;9:929-936.
5. Belinson JL, Wu RF, Belinson SE, et al. A population based clinical trial comparing endocervical high-risk HPV testing using Hybrid Capture II and Cervista from the SHENCCAST II Study. Am J Clin Pathol. 2011;135:790-795.
6. Söderlund-Strand A, Dillner J, Carlson J. High-throughput genotyping of oncogenic human papilloma viruses with MALDI-TOF mass spectrometry. Clin Chem. 2008;54:86-92. (Pubitemid 351182600)
7. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
8. Clavel C, Masure M, Bory JP, et al. Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women. Br J Cancer. 1999;80:1306-1311. (Pubitemid 29308597)
9. Day SP, Hudson A, Mast A, et al. Analytical performance of the investigational use only Cervista HPV HR test as determined by a multi-center study. J Clin Virol. 2009;45(suppl 1):S63-S72.
10. Belinson JL, Qiao YL, Pretorius RG, et al. Shanxi Province cervical cancer screening study: a cross-sectional comparative trial of multiple techniques to detect cervical intraepithelial neoplasia. Gynecol Oncol. 2001;83:439-444. (Pubitemid 33033096)
11. Pepe MS, Janes H, Longton G, et al. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol. 2004;159:882-890. (Pubitemid 38657490)
12. Belinson, JL, Pretorius RG, Enerson C, et al. The Mexican Cervical Cancer Screening Trial (MECCS): self-sampling for the human papillomavirus with unaided visual inspection as a secondary screen. Int J Gynecol Cancer. 2009;19:27-32.
13. Wright TC Jr, Denny L, Kuhn L, et al. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA. 2000;283:81-86. (Pubitemid 30038387)
14. Leinonen M, Nieminen P, Kotaniemi-Talonen L, et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst. 2009;101:1612-1623.
15. Samarawardana P, Dehn DL, Singh M, et al. p16(INK4a) is superior to high-risk human papillomavirus testing in cervical cytology for the prediction of underlying high-grade dysplasia. Cancer Cytopathol. 2010;118:146-156.